Eli Lilly: Favorable Development Continue Regarding Anti-Obesity Drug Franchise (NYSE:LLY)

Semaglutide auto injector pen isolated

KKStock/iStock via Getty Images

Over the past two weeks, there has been a spate of favorable news regarding the anti-obesity drug class, and Eli Lilly’s (NYSE:LLY) Zepbound in particular. Most importantly, Zepbound (tirzepatide) was approved in the US and the EMA recommended approval

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *